Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 21, 2022
Cambrex entered an agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
read more
Tuesday, November 20, 2018
Cambrex has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.
read more
Cambrex has announced three senior appointments to further support the Contract development and Manufacturing Organization company.
read more
Cambrex announced Tom Loewald has been named Chief Executive Officer and a member of the company’s Board of Directors, effective September 7th.
read more
Wednesday, November 08, 2017
Cambrex announced that it has completed an expansion of cGMP small scale capacity at its Charles City, Iowa plant.
read more
Cambrex announced that it is investing approximately $3 million to increase the capacity and efficiency of one of its cGMP manufacturing facilities at its site in Paullo, Milan, Italy.
read more
Wednesday, August 09, 2017
Cambrex Corporation announced that it is to invest $24 million in a new facility to manufacture highly potent APIs (HPAPIs) at its Charles City, Iowa plant.
read more
Cambrex announced the completion of an investment project at its facility in Tallinn, Estonia to upgrade its kilogram-scale laboratory to undertake the manufacture of pharmaceutical intermediates under current good manufacturing practice (CGMP) ...
read more
Cambrex announced it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity.
read more
Tuesday, January 30, 2018
Cambrex announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant.
read more
Cambrex Corporation will expand research and development capabilities at its site in Paullo, Milan, Italy.
read more
Wednesday, March 27, 2019
Cambrex announced it will double the liquid packaging capacity and weekly output at its Mirabel, Québec site in Canada.
read more
Wednesday, April 13, 2022
Cambrex announced the completion of a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Charles City, Iowa facility.
read more
Cambrex announced that it has completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA.
read more
Wednesday, January 02, 2019
Cambrex has completed the acquisition of Avista Pharma Solutions, a contract development, manufacturing, and testing organization, from Ampersand Capital Partners.
read more